ストックスクリーナーアプリを入手
1.735
0.87%
0.015
アフターアワーズ：
1.75
0.015
+0.86%
前日終値:
$1.72
開ける：
$1.75
24時間の取引高:
36,976
Relative Volume:
0.20
時価総額：
$18.12M
収益：
$1.85M
当期純損益:
$-5.26M
株価収益率:
-1.8356
EPS:
-0.9452
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-9.40%
1か月 パフォーマンス:
-31.42%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$1.68
$1.8153
1週間の範囲:
$1.68
$1.99
52週間の値動き範囲:
$1.51
$14.09
20 20 Biolabs Inc Stock (AIDX) Company Profile
Compare AIDX vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AIDX
20 20 Biolabs Inc
|
1.735 | 17.96M | 1.85M | -5.26M | 0 | -0.9452 |
ABT
Abbott Laboratories
|
101.56 | 175.59B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
341.24 | 132.47B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.10 | 113.14B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
64.61 | 94.85B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
78.20 | 45.09B | 6.07B | 1.06B | 1.34B | 1.8063 |
20 20 Biolabs Inc (AIDX) 最新ニュース
20/20 Biolabs (AIDX) Stock Chart and Price History 2026 - MarketBeat
BIO-key International, 20/20 Biolabs, Society Pass, and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
20/20 Biolabs (NASDAQ: AIDX) resale prospectus: 10.105M shares may be sold - Stock Titan
15.16M shares available for resale as 20/20 Biolabs (NASDAQ: AIDX) direct listing - Stock Titan
[EFFECT] 20/20 Biolabs, Inc. SEC Filing - Stock Titan
20/20 BIOLABS INC Company Profile & Introduction - Moomoo
AIDX: 20/20 Biolabs Inc.Comparison to Industry - Zacks Investment Research
Dividend History20/20 Biolabs Inc. (AIDX) - Zacks Investment Research
AIDX Price Today: 20/20 Biolabs, Inc. Stock Price, Quote & Chart - MEXC
20/20 BioLabs Selected by Evexia Diagnostics to Offer OneTest™ for Cancer Through Evexia Platform - Sahm
Multi-Cancer Early Detection Test Added to Evexia Diagnostics Platform - Clinical Lab Products
Cancer test reaches 40,000 practitioners through Evexia platform - Stock Titan
20/20 Biolabs (AIDX) CFO receives 100,000-share stock option grant - Stock Titan
COO of 20/20 Biolabs (AIDX) granted 150,000 options at $1.88 - Stock Titan
Resale of 10.1M 20/20 Biolabs (Nasdaq: AIDX) shares amid losses - Stock Titan
20/20 Biolabs (NASDAQ: AIDX) 15.16M-share resale registration - Stock Titan
AIDX : 20/20 Biolabs Inc. Key Company Metrics & Non-finance Metrics - Zacks Investment Research
20/20 Biolabs, Inc. (AIDX) stock price, news, quote and history - Yahoo Finance Singapore
20/20 BioLabs (AIDX) Reports 17% Revenue Growth in 2025 and Eyes Significant Expansion in 2026 with AI-Powered Cancer Detection Blood Tests - Minichart
20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress - The Manila Times
All News for AIDX : 20/20 Biolabs Inc. - Zacks Investment Research
20/20 BioLabs (AIDX) grows 2025 revenue 17% and narrows annual net loss - Stock Titan
20/20 Biolabs 10-K: Revenues $2.05M, Net Loss $(3.74)M - TradingView — Track All Markets
20/20 Biolabs (NASDAQ: AIDX) outlines AI blood tests, longevity and growth - Stock Titan
20/20 Biolabs, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Maryland funds firefighter cancer tests as 20/20 lifts margins - Stock Titan
AIDX | 20/20 Biolabs, Inc. Common Institutional Ownership - Quiver Quantitative
AIDX | 20/20 Biolabs, Inc. Common Stock Data, Price & News - Quiver Quantitative
20/20 Biolabs Unchanged on News - Baystreet.ca
20/20 BioLabs announces grants for Maryland fire departments to procure OneTest - TipRanks
Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs’ OneTest ™ Multi-Cancer Early Detection Blood Test - The Manila Times
20/20 BioLabs licenses kidney disease prediction technology from ROKIT Healthcare - MSN
Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs' OneTest Multi-Cancer Early Detection Blood Test - Bitget
20/20 BioLabs licenses kidney disease prediction technology By Investing.com - Investing.com India
What's going on with 20/20 Biolabs stock? - MSN
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
20/20 BioLabs enters exclusive technology license, access agreement with Rokit - TipRanks
What's Going On With 20/20 Biolabs Stock? - Benzinga
20/20 Biolabs Faces Decline Amid Market Rut - timothysykes.com
20/20 BioLabs licenses kidney disease prediction technology - Investing.com
20/20 Biolabs shares are trading lower after ... - Benzinga
20/20 BioLabs Announces Exclusive U.S. License Agreement with ROKIT Healthcare to Integrate Advanced CKD Prediction Technology into Its Longevity Test Program - The Manila Times
20/20 BioLabs Announces Exclusive U.S. License Agreement - GlobeNewswire
What is the current Price Target and Forecast for 20/20 Biolabs Inc. (AIDX) - Zacks Investment Research
What date does 20/20 Biolabs Inc.'s (AIDX) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
AIDX Stock Price, News & Analysis - Stock Titan
Debt to equity ratio of 20/20 Biolabs, Inc. – NASDAQ:AIDX - TradingView
20/20 Biolabs Inc. (AIDX) Total Long Term Debt (Quarterly) - Zacks Investment Research
20/20 Biolabs Inc. (AIDX) Return On Assets (TTM) - Zacks Investment Research
20/20 Biolabs Inc. (AIDX) Total Expenses (TTM) - zacks.com
20/20 Biolabs Inc. (AIDX) Price Book Value - Zacks Investment Research
20 20 Biolabs Inc (AIDX) 財務データ
収益
当期純利益
現金流量
EPS
2.40%
0.00%
大文字化:
|
ボリューム (24 時間):